Neurocrine Biosciences Officer Reports PRSU Vesting & Rule 10b5-1 Stock Sale
NEUROCRINE BIOSCIENCES INC
Subscribe to track NBIX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š Insider Sale Alert: NEUROCRINE BIOSCIENCES INC ($NBIX) š¤ Insider: Boyer David W. (Chief Corp. Affairs Officer) š Transaction Date: 2026-09-14 š Transaction: Sold 826 shares @ $157.45 ($130,050.56) š¦ Holdings After: 8,722 shares š Notes: Sale executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026. Includes prior vesting of 3,587 PRSUs and 1,936 shares withheld for taxes.
Comprehensive Analysis
Executive Summary
On September 15, 2026, David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences Inc ($NBIX), reported transactions in the company's common stock:
- PRSU Vesting (2026-09-11): Acquired 3,587 shares upon certification of performance metrics.
- Tax Withholding (2026-09-11): 1,936 shares withheld at $156.22 per share ($302,441.92 total value) to satisfy tax liabilities.
- Open Market Sale (2026-09-14): Sold 826 shares at a weighted average price of $157.4462 for total proceeds of $130,050.56 under a pre-established Rule 10b5-1 trading plan.
Holdings Analysis
- Post-Transaction Holdings: 8,722 shares directly owned.
- Context: The sale represents routine equity monetization under a 10b5-1 plan established on February 23, 2026, alongside standard PRSU vesting and tax-withholding events. Trading significance is assessed as Low.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.